Takeda Eyes Plasma Therapy for Covid-19 Patients

Via The Street

“Japanese drug maker Takeda is planning to use an old therapy technology for a new disease, Covid-19. The company is developing a plasma-derived therapy, dubbed TAK-888, that would be similar to plasma-based treatments previously used on other severe acute viral infections, including during the Ebola crisis, that is based on technology believed to date back as far as the flu of 1918. Takeda is one of several companies — including several U.S. ones, racing for a treatment for the disease. “

“By concentrating the virus-specific antibodies from plasma collected from people who have already recovered from Covid-19, the disease caused by the newly discovered coronavirus, TAK-888 could be used to treat severely ill patients and — possibly — help their at-risk health care workers develop immunity.”

Read The Street’s interview with Julie Kim, president of Takeda’s plasma-derived therapies business

MAA COVID-19 INFORMATION DISCLAIMER:

The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service.   The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.  

The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via this email or other communications.

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER